Evidence map›Paper›PMID 29930174›Full record

ArticleEMBO molecular medicine2018

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

Daniel E Foxler, Katherine S Bridge, John G Foster, Paul Grevitt, Sean Curry, Kunal M Shah, Kathryn M Davidson, Ai Nagano, Emanuela Gadaleta, Hefin I Rhys and 17 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. ClonalLife science alliance · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance.Combinatorial chemistry & high throughput screening · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Hypoxia Pathway Proteins and Their Impact on the Blood Vasculature.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Daniel E FoxlerCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0003-3753-0278
Katherine S BridgeCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0003-1516-1459
John G FosterCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-8591-0833
Paul GrevittCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-8224-1315
Sean CurryFaculty of Medicine and Life Sciences, University of Nottingham, Nottingham, UK.
Kunal M ShahCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-4508-9606
Kathryn M DavidsonCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-7922-2367
Ai NaganoCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Emanuela GadaletaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-5740-6293
Hefin I RhysThe Francis Crick Institute, London, UK.ORCID 0000-0002-7385-9014
Paul T KennedyCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-5668-9132
Miguel A HermidaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-2633-4119
Ting-Yu ChangInstitute of Microbiology and Immunology, National Yang Ming University, Taipei City, Taiwan.ORCID 0000-0002-0561-2757
Peter E ShawFaculty of Medicine and Life Sciences, University of Nottingham, Nottingham, UK.ORCID 0000-0002-2598-4283
Louise E ReynoldsCentre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-6075-1808
Tristan R McKaySchool of Healthcare Science, Manchester Metropolitan University, Manchester, UK.ORCID 0000-0002-9128-9115
Hsei-Wei WangInstitute of Microbiology and Immunology, National Yang Ming University, Taipei City, Taiwan.
Paulo S RibeiroCentre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-6020-6321
Michael J PlevinDepartment of Biology, University of York, York, UK.ORCID 0000-0003-2057-8291
Dimitris LagosCentre for Immunology and Infection, Hull York Medical School and Department of Biology, University of York, York, UK.ORCID 0000-0003-0637-281X
Nicholas R LemoineCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-8675-058X
Prabhakar RajanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-8064-9878
Trevor A GrahamCentre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-9582-1597
Claude ChelalaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-2488-0669
Kairbaan M Hodivala-DilkeCentre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-2859-749X
Ian SpendloveFaculty of Medicine and Life Sciences, University of Nottingham, Nottingham, UK.ORCID 0000-0002-7480-3768
Tyson V SharpCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK t.sharp@qmul.ac.uk.ORCID 0000-0003-1861-7984
Queen Mary University of London · GBUniversity of Nottingham · GBNational Yang Ming Chiao Tung University · TWUniversity of York · GBManchester Metropolitan University · GBThe Francis Crick Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L027755/1Biotechnology and Biological Sciences Research Council BB/N018818/1Cancer Research UK 12007Cancer Research UK 15339Cancer Research UK 18673Cancer Research UK C16420/A18066Cancer Research UK C19198/A15339Cancer Research UK C355/A25137Cancer Research UK CRUK‐A12733Medical Research Council MR/L008505/1Medical Research Council MR/N009185/1
6 · The paper itself

Abstract

The adaptive cellular response to low oxygen tensions is mediated by the hypoxia-inducible factors (HIFs), a family of heterodimeric transcription factors composed of HIF-α and HIF-β subunits. Prolonged HIF expression is a key contributor to cellular transformation, tumorigenesis and metastasis. As such, HIF degradation under hypoxic conditions is an essential homeostatic and tumour-suppressive mechanism. LIMD1 complexes with PHD2 and VHL in physiological oxygen levels (normoxia) to facilitate proteasomal degradation of the HIF-α subunit. Here, we identify

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinomaAdultAgedAged, 80 and overAnimalsCarcinogenesisCell HypoxiaCell Line, TumorFeedback, PhysiologicalFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsLung NeoplasmsHypoxia-Inducible Factor 1, alpha SubunitIntracellular Signaling Peptides and ProteinsLIMD1 protein, humanLIM Domain ProteinsVascular Endothelial Growth Factor AVEGFA protein, humanadaptive hypoxic responseHIF‐1LIMD1lung cancertumour suppressor

Identifiers

PMID29930174
PMCPMC6079541
OpenAlexW2809498454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.